Speaking with Dr. Narjust Florez, Prof. Solomon discusses the design and results of the ALINA trial. Read more
The US approved alectinib as adjuvant treatment based on a significant DFS benefit compared to chemotherapy. Read more
Drs. Laila Roisman and Nir Peled envision a future where artificial intelligence elevates personalized medicine in ways once thought impossible. Read more
The UK recently moved to ban smoking for individuals born after 2009 while the US delayed implementation of a ban on menthol cigarettes—again. Read more
Drs. Christi M.J. Steendam and Sushil K. Badrising review studies comparing outcomes of various treatment regimens in the search for the best-performing approach. Read more
Dr. Jeffrey D. Bradley presented the data from the phase III study of durvalumab in combination with and following chemoradiotherapy for patients with unresectable, stage III NSCLC during the 2024 European Lung Cancer Congress. Read more
Compared to chemotherapy alone, the addition of the EGFR-MET bispecific antibody significantly prolonged progression-free survival after subsequent therapy, said Dr. Ryan Gentzler during the European Lung Cancer Congress. Read more
In a recent interview, Dr. Lecia V. Sequist, a member of the team behind the Sybil AI algorithm, discusses how technology may soon be able to predict who will develop lung cancer. Read more
US FDA grants accelerated approval of HER2-targeting antibody drug conjugate; China accepts supplemental new drug application for savolitinib. Read more
During the European Lung Cancer Congress, Dr. Natalia Valdiviezo presented the data, which favored frontline osimertinib plus chemotherapy compared to osimertinib alone for patients with EGFR-mutated NSCLC. Read more